|
|
|
市場調查報告書
高內涵分析（HCA）的技術・應用・市場分析
High Content Analysis: Technologies, Applications, Market Analysis
|
高內涵分析（HCA）的技術・應用・市場分析 是由出版商Insight Pharma Reports在2007年05月所出版的。
這份英文市場調查報告書包含58 pages 價格從美金1498起跳。
專門於基因領域調查，並獲全球高度評價的美國市調公司 Insight Pharma Reports (總公司：Massachusetts state) ，出版了一本關於高內涵分析（HCA）技術・應用・市場的詳細調查報告書 "High Content Analysis: Technologies, Applications, Market Analysis" 。
本報告書內容包括：HCA相關實踐趨勢・計畫・意見、應用・企業・IT/硬體/試藥別市場分析及預測、技術及應用趨勢、促進及阻礙市場發展因素、主力企業的定位等。包含圖表共計74頁的內容綱要摘記如下：
第1章 介紹
- HCA的定義
- HTS與HCA的類似性
- HCA與HTS重覆的地方
第2章 HCA的現況
- 介紹
- 利用領域
- LCA（Live Cell Analysis－活體細胞分析）
- 一般應用
- 一般分析報告
- 顯像相關分析
- 共焦機器
- 新開發
- 軟體相關的課題
- 專業軟體供應企業的發展預測
- 資料標準化
第3章 企業・趨勢・市場
- 市場中的領先企業
- 市場趨勢
- HCA vs HTS
- 進入障礙
- 技術展望
第4章 HCA市場分析
- 促進及阻礙市場發展因素
- 主力企業的定位
- 花在所有權上的成本
- HCA應用分析
- 市場力學
附錄
圖表
Abstract
This new Insight Pharma report from Cambridge Healthtech Institute delivers
the data and the analysis you need to stay on top of this fast-changing market:
- Quantitative survey (N=60) of the practices, plans, and views of
researchers involved with HCA
- Market segmentation and forecast ($ share by application, by company, and
by IT/hardware/reagents)
- Thorough review of HCA technologies and applications, including new
developments and challenges
- Total cost of ownership analysis
- Main market drivers and barriers
- Thought-leader interviews with leading researchers in industry and academia
- Position of the dominant players such as Cellomics/Fisher, GE, MDS, BD,
and Evotec; and of up-and-coming smaller players
High content analysis (HCA) is the convergence between cell-based assays,
high-resolution fluorescence imaging, automation and advanced image processing
and analysis software. It has been widely adopted in the pharmaceutical and
biotech industries for target identification and validation and as secondary
screens to reveal potential toxicities or to elucidate a drug' s mechanism of
action. In particular, HCA has made inroads into R&D applications where high
throughput screening (HTS) has proven inadequate, such as measuring multiple
biological pathways simultaneously, or revealing off-target drug effects. HCA
has stepped into this void by demonstrating how particular proteins are
affected by the application of a molecule to the cell line of interest.
We estimate the total market for HCA systems and software at nearly $80
million in 2006, with a leveling off during 2007-2008, and a sharp rise
thereafter as the pharmaceutical sector fully embraces HCA applications in
secondary and primary screening. We estimate the reagent market at
approximately $125 million, with growth driven by an increase in wells/study
and growth in the academic sector. As of 2006, there is still strong interest
in the potential of HCA applications; however, the systems have not yet fully
closed the gap from attracting early adopters and technology drivers to
emerging as a mainstream market. Interesting dynamics at work in the market
include the emergence of a market for kits and assays, and the rise of the
academic sector as a significant percentage of the application base for HCA.
HCA end users were polled for technical features they would like to see in HCA
instruments. Desired technical advances were split pretty evenly across a
variety of features, with automated data collection and analysis (55% of
respondents) and increased speed (53%) leading the list.
Cost continues to be a key barrier to adoption of HCA, especially among
smaller companies and academic institutions. Prices have decreased somewhat
over the past 2 years, but cost was nevertheless the main reason cited by
survey respondents (59%). Difficulty of use of the image analysis software
came in a close second at 49.2%. Users report that software systems are rarely
intuitive and can require extensive training to accomplish even simple
procedures. It is expected that third-party software developers will play a
role in improving HCA software usability, but they have only penetrated a
small (approximately 10%) fraction of the market, with most researchers using
the software that was shipped with the instrument. Also in the survey, 41% of
respondents cited lack of flexibility of image analysis software.
High Content Analysis: Technologies, Applications, Market Analysis is a
must-read for both vendors and users of HCA systems who need to understand the
dynamics and the direction of this important market.
Table of Contents
Chapter 1
- INTRODUCTION
- 1.1. HCA Defined
- 1.2. Similarities Between HCA and high-throughput screening
- 1.3. Overlap Between HCA and HTS
Chapter 2
- HCA: CURRENT STATE
- 2.1. Introduction
- 2.2. Use Categories
- Primary Screening
- Secondary Screening and Toxicology
- 2.3. Live-Cell Analysis
- Kinetic Analyses vs. Fixed-Cell Analyses
- 2.4. Common Applications
- 2.5. Common Assays
- 2.6. Imaging Consideration
- 2.7. Confocal Instruments
- 2.8. New Developments
- 2.9. Software Challenges
- 2.10. A Third-Party Software Provider' s Perspective
- 2.11. Data Standardization
Chapter 3
- COMPANIES, TRENDS, AND MARKETS
- 3.1. Leaders
- 3.2. Trends
- 3.3. HCA vs. HTS
- 3.4. Barriers to Entry
- 3.5. Technology Wishes
- Caliper and Microfluidics
Chapter 4
- HCA MARKET ANALYSIS
- 4.1. Main Drivers and Barriers
- 4.2. Position of Dominant Players
- An Emerging Market for Kits and Assays
- 4.3. Analysis of Total Cost of Ownership
- 4.4. Analysis of HCA Applications
- Emergence of the Academic Market
- 4.5. Market Dynamics: Big Fish Eating Little Fish
APPENDIX
- CHI INSIGHT PHARMA REPORTS - HIGH-CONTENT ANALYSIS SURVEY - MARCH 2007
REFERENCES
COMPANY INDEX WITH WEB ADDRESSES
EXPERTS INTERVIEWED FOR THIS REPORT
- Andrea Chow, vice president of microfluidics R&D, Caliper Life Sciences
- Cathy Howat, marketing director for InCell Analyzer in Europe, GE
Healthcare
- Mark Collins, marketing manager, cellular imaging and analysis business,
Cellomics
- Peter O' Brien, University College Dublin
- Anthony Davies, Institute of Molecular Medicine, Trinity College, Dublin
- Jason Swedlow, University of Dundee, Open Microscopy Environment
- Nick Arini, product marketing manager Definiens
- Kurt Herrenknecht, business development, Europe, Evotec
- Ralph Garippa, research leader, Roche Discovery Technologies
|
 |
